Direct Healthcare Professional Communication (DHPC) on chlormadinone acetate and nomegestrol acetate: Measures to minimise the risk of meningioma
2022.11.09
Active substance: chlormadinone, nomegestrol
The marketing authorisation holders of chlormadinone- and nomegestrol- containing medicines in agreement with the European Medicines Agency (EMA) and the Federal Institute for Drugs and Medical Devices (BfArM) would like to inform you that medicinal products containing chlormadinone acetate (5-10 mg/tablet) or nomegestrol acetate (3.75 -5 mg/tablet) are only indicated when other interventions are considered inappropriate. Treatment should be restricted to the lowest effective dose and shortest duration.
Information on the referral can be found at the following link:
The Direct Healthcare Professional Communication (DHPC) can be found here:
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN